What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Diabetes mellitus
- Type 2 diabetes
Michael A. Nauck mainly investigates Internal medicine, Endocrinology, Type 2 diabetes, Diabetes mellitus and Insulin.
His work carried out in the field of Internal medicine brings together such families of science as Liraglutide and Placebo.
His Glucagon-like peptide-1, Incretin, Glucagon, Gastric inhibitory polypeptide and Gastrointestinal hormone study are his primary interests in Endocrinology.
His study in Glucagon is interdisciplinary in nature, drawing from both Glucose clamp technique, Pancreatic hormone and Glucose homeostasis.
His studies in Type 2 diabetes integrate themes in fields like Tolerability, Randomized controlled trial and Glycemic.
Michael A. Nauck combines subjects such as Disease management and Intensive care medicine with his study of Diabetes mellitus.
His most cited work include:
- Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (3586 citations)
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (3062 citations)
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes (2940 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Endocrinology, Type 2 diabetes, Diabetes mellitus and Insulin are his primary areas of study.
His Internal medicine research is multidisciplinary, incorporating perspectives in Liraglutide, Placebo, Glucagon-like peptide-1 and Gastroenterology.
Endocrinology is closely attributed to Gastric emptying in his research.
His Type 2 diabetes research includes themes of Metformin and Randomized controlled trial, Surgery.
His research in Diabetes mellitus intersects with topics in Myocardial infarction, Cardiology and Pancreatitis.
His work on Pancreatic hormone, Hypoglycemia and C-peptide as part of his general Insulin study is frequently connected to Chemistry, thereby bridging the divide between different branches of science.
He most often published in these fields:
- Internal medicine (83.87%)
- Endocrinology (59.82%)
- Type 2 diabetes (42.52%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (83.87%)
- Type 2 diabetes (42.52%)
- Diabetes mellitus (37.54%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Internal medicine, Type 2 diabetes, Diabetes mellitus, Liraglutide and Placebo.
Michael A. Nauck interconnects Gastroenterology, Endocrinology and Semaglutide in the investigation of issues within Internal medicine.
His study in the field of Incretin also crosses realms of Chemistry.
His studies deal with areas such as Clinical trial, Cross-sectional study, Nephropathy, Glucagon-like peptide 1 receptor and Proportional hazards model as well as Type 2 diabetes.
His Diabetes mellitus research incorporates themes from Gastric emptying and Bioinformatics.
His Insulin research is multidisciplinary, incorporating elements of Glucagon-like peptide-1 and Type 1 diabetes.
Between 2017 and 2021, his most popular works were:
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial (555 citations)
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial (210 citations)
- Incretin hormones: Their role in health and disease. (173 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Diabetes mellitus
- Type 2 diabetes
His scientific interests lie mostly in Internal medicine, Liraglutide, Type 2 diabetes, Diabetes mellitus and Placebo.
His Internal medicine study combines topics in areas such as Gastroenterology and Endocrinology.
His Liraglutide research incorporates elements of Stroke, Myocardial infarction, Cardiology and Mace.
His research integrates issues of Rate ratio and Glucagon-like peptide 1 receptor in his study of Type 2 diabetes.
His Diabetes mellitus research includes elements of Gynecology and Angiology.
The various areas that he examines in his Placebo study include Tolerability and Hazard ratio.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
